Show
Sort by
-
CAR-T treatment of pediatric AML : a long and winding road
-
The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1
-
- Journal Article
- A1
- open access
The transcription factor ETS1 is an important regulator of human NK cell development and terminal differentiation
-
Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma
-
Chemotherapy at the wheel of ALL relapse
-
- Journal Article
- open access
Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura
-
- Conference Paper
- C3
- open access
Results from the completed dose-escalation of the hematological arm of the Phase I Think Study evaluating multiple infusions of NKG2D-based CAR T-cells as standalone therapy in relapse/refractory acute myeloid leukemia and myelodysplastic syndrome patients
-
CD20-TCB, a novel T-cell-engaging bispecific antibody, can be safely combined with the anti-PD-L1 antibody Atezolizumab in relapsed or refractory B-cell non-Hodgkin lymphoma
-
Priority lane to cDC1 open for IRF8⁺ progenitors
-
Real world population-based exploration of the pathology subtyping and treatment-modalities of diffuse large B-cell lymphoma in Belgium in relation to survival